MLYS
NASDAQMineralys Therapeutics Inc.
Price$26.35-3.89 (-12.86%)
2026-05-212026-08-25
News · 26 weeks95+8%
2026-03-012026-08-23
Mix4790d
- SEC Filings23(49%)
- Insider14(30%)
- Other7(15%)
- Offering2(4%)
- Earnings1(2%)
Latest news
25 items- INSIDERChief Commercial Officer Warren Eric exercised 7,437 shares at a strike of $13.24 and sold $193,189 worth of shares (7,437 units at $25.98) as part of a pre-agreed trading plan (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- PRMineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on August 10, 2026, a majority of the independent directors of Mineralys’ Board of Directors granted an inducement stock option award covering 135,000 shares and an inducement restricted stock unit award covering 102,400 shares of Mineralys common stock to Dr. Terry Ferguson, Mineralys’ newly appointed Chief Medical Officer.
- INSIDERChief Medical Officer Ferguson James J. Iii was granted 102,400 shares (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ferguson James J. Iii3 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- INSIDERChief Medical Officer Rodman David Malcom exercised 2,170 shares at a strike of $16.00 and sold $58,785 worth of shares (2,170 units at $27.09) as part of a pre-agreed trading plan (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 10-Q filed by Mineralys Therapeutics Inc.10-Q - Mineralys Therapeutics, Inc. (0001933414) (Filer)
- SECMineralys Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)
- PRMineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update– PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval – – Appoints accomplished cardiovascular medicine executive Dr. Terry Ferguson as Chief Medical Officer to lead the Company’s medical and late-stage clinical activities – – Strengthened balance sheet and enhanced the long-term economics of lorundrostat through strategic financing initiatives and the repurchase of the Tanabe royalty obligation – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosteron
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Mineralys Therapeutics Inc.SCHEDULE 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- PRMineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced it will report its financial results from the second quarter ended June 30, 2026, after the financial markets close on Tuesday, August 11, 2026. Tuesday, August 11th @ 4:30 p.m. ETDomestic:1-877-704-4453International:1-201-389-0920Conference ID:13760792Webcast:Link A live webcast of the conference call may also be found on th
- PRMineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)RADNOR, Pa., July 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that (1) on July 17, 2026, the Compensation Committee of Mineralys’ Board of Directors (the Compensation Committee) granted an inducement stock option award covering 14,880 shares and an inducement restricted stock unit award covering 11,160 shares of Mineralys common stock to a new non-executive employee, and (2) on J
- INSIDERChief Commercial Officer Warren Eric exercised 7,438 shares at a strike of $13.24 and sold $199,885 worth of shares (7,438 units at $26.87) as part of a pre-agreed trading plan (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- INSIDERChief Medical Officer Rodman David Malcom sold $11,036 worth of shares (416 units at $26.53) as part of a pre-agreed trading plan and exercised 416 shares at a strike of $15.44 (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- INSIDERChief Executive Officer Congleton Jon sold $291,441 worth of shares (10,700 units at $27.24) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 603,621 units (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- INSIDERChief Medical Officer Rodman David Malcom exercised 14,058 shares at a strike of $7.28 and sold $556,671 worth of shares (20,407 units at $27.28) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 51,384 units (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECAmendment: SEC Form 144/A filed by Mineralys Therapeutics Inc.144/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
MLYS FAQ
6 questionsWhere does MLYS stock trade?
Mineralys Therapeutics Inc. (MLYS) is listed on NASDAQ.What sector and industry is MLYS in?
Mineralys Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Mineralys Therapeutics Inc. go public?
Mineralys Therapeutics Inc. (MLYS) completed its IPO in 2023.What are analysts saying about MLYS?
Mineralys Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2026-04-27. Recent price targets range from $1500.00 to $3900.00.What companies are similar to MLYS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MLYS side-by-side with any of them on Quantisnow.How can I track MLYS on Quantisnow?
Quantisnow aggregates Mineralys Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MLYS to receive live email and push alerts on every new disclosure.